- Cardiovascular Systems Inc.
- Cardiovascular Systems
- Neose Technologies Inc.
- AtheroGenics Inc.
- Orchestra Therapeutics Inc.
- Avalon Pharmaceuticals Inc.
- Exelixis Inc.
- ZymoGenetics Inc.
- Array BioPharma Inc.
- Cadence Pharmaceuticals Inc.
- Pfizer Inc.
- GlaxoSmithKline PLC
- Haptogen Ltd.
- Merck & Co. Inc.
- Bristol-Myers Squibb Co.
- Eli Lilly & Co.
- Zogenix Inc.
- Transcept Pharmaceuticals Inc.
- Orexigen Therapeutics Inc.
- Biovail Corp.
- Prestwick Pharmaceuticals Inc.
- Shire PLC
- Zymenex AS
- Jerini AG
- Purdue Pharma LP
- Genzyme Corp.
- Genzyme Drug Discovery & Development
- Ionis Pharmaceuticals Inc.
- PTC Therapeutics Inc.
- Osiris Therapeutics Inc.
- Exelixis signs debt deal with Deerfield; expired
- Hospital products company Cadence nets $57.8mm with IPO
- Wyeth Pharmaceuticals buys Haptogen
- Biovail affirms CNS focus in $100mm Prestwick takeover
- Shire pays $135mm for Zymenex's Metazym for MLD
- Shire proposes €328mm acquisition of Jerini AG
- Genzyme to buy GelTex in $1bn cash/stock deal
- Genzyme acquires SangStat Medical for $596mm
- Genzyme acquires Ilex for $1bn
- Genzyme acquires Bone Care International for $600mm
- Genzyme and Isis enter $1.2bn CV collaboration
- Genzyme helps PTC develop and commercialize PTC124; terminated
- Genzyme gets rights to Osiris's Prochymal and Chondrogen; deal terminated
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. email@example.com.
All fields are required.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.